Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
925 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07657897 | The Impact of Anaesthesia and Sedation on Inflammation and NETosis in Hepatocellular Carcinoma Ablation | recruiting | N/A | 100 | Iuliu Hatieganu University of Medicine and PharmacyOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05429632 | Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT(MO-TRANS) | recruiting | Phase 3 | 366 | Priothera SASINDUSTRY | 14 | Jul 17, 2026 |
| clinicaltrials |
| NCT06413706 | A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | active not recruiting | Phase 2 | 45 | Eli Lilly and CompanyINDUSTRY | 10 | Jul 17, 2026 | clinicaltrials |
| NCT03043872 | Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)(CASPIAN) | active not recruiting | Phase 3 | 987 | AstraZenecaINDUSTRY | 23 | Jul 16, 2026 | clinicaltrials |
| NCT04700124 | Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)(KEYNOTE-B15) | active not recruiting | Phase 3 | 808 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Jul 16, 2026 | clinicaltrials |
| NCT04717414 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions(INDEPENDENCE) | active not recruiting | Phase 3 | 313 | CelgeneINDUSTRY | 26 | Jul 16, 2026 | clinicaltrials |
| NCT03456076 | A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 257 | Hoffmann-La RocheINDUSTRY | 27 | Jul 15, 2026 | clinicaltrials |
| NCT05450692 | A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy(LATIFY) | active not recruiting | Phase 3 | 594 | AstraZenecaINDUSTRY | 23 | Jul 13, 2026 | clinicaltrials |
| NCT03148418 | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | active not recruiting | Phase 3 | 382 | Hoffmann-La RocheINDUSTRY | 32 | Jul 10, 2026 | clinicaltrials |
| NCT03737643 | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients(DUO-O) | active not recruiting | Phase 3 | 1,407 | AstraZenecaINDUSTRY | 20 | Jul 7, 2026 | clinicaltrials |
| NCT04464226 | Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | active not recruiting | Phase 3 | 402 | BayerINDUSTRY | 39 | Jul 7, 2026 | clinicaltrials |
| NCT06153238 | A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma | completed | Phase 1 | 322 | SandozINDUSTRY | 18 | Jul 7, 2026 | clinicaltrials |
| NCT06348199 | A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 555 | Samsung Bioepis Co., Ltd.INDUSTRY | 14 | Jul 7, 2026 | clinicaltrials |
| NCT04205812 | Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer(POD1UM-304) | completed | Phase 3 | 583 | Incyte CorporationINDUSTRY | 17 | Jul 6, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT05120349 | A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection(ADAURA2) | active not recruiting | Phase 3 | 390 | AstraZenecaINDUSTRY | 20 | Jul 6, 2026 | clinicaltrials |
| NCT05608291 | A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | active not recruiting | Phase 3 | 1,564 | Regeneron PharmaceuticalsINDUSTRY | 22 | Jul 6, 2026 | clinicaltrials |
| NCT06356129 | Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma(GOLSEEK-1) | active not recruiting | Phase 3 | 850 | CelgeneINDUSTRY | 38 | Jul 6, 2026 | clinicaltrials |
| NCT04895722 | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008). | active not recruiting | Phase 2 | 302 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Jul 2, 2026 | clinicaltrials |
| NCT06578247 | Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML(QuANTUM-WILD) | active not recruiting | Phase 3 | 700 | Daiichi SankyoINDUSTRY | 28 | Jul 2, 2026 | clinicaltrials |
| NCT06819007 | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)(DO-01) | recruiting | Phase 3 | 582 | Daiichi SankyoINDUSTRY | 25 | Jul 2, 2026 | clinicaltrials |
| NCT04655976 | Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy(COSTAR Lung) | active not recruiting | Phase 2 / Phase 3 | 758 | GlaxoSmithKlineINDUSTRY | 24 | Jul 1, 2026 | clinicaltrials |
| NCT05288166 | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)(CYCLONE 3) | active not recruiting | Phase 3 | 925 | Eli Lilly and CompanyINDUSTRY | 24 | Jul 1, 2026 | clinicaltrials |
| NCT06440629 | Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)(RA-DRUM) | active not recruiting | Phase 4 | 387 | Diakonhjemmet HospitalOTHER | 6 | Jul 1, 2026 | clinicaltrials |
| NCT03600883 | A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) | completed | Phase 1 / Phase 2 | 713 | AmgenINDUSTRY | 16 | Jun 30, 2026 | clinicaltrials |
| NCT02393859 | Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 3 | 111 | AmgenINDUSTRY | 24 | Jun 26, 2026 | clinicaltrials |
| NCT07575347 | Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)(PERIO-RA-RE) | recruiting | — | 100 | Stefan LujinschiOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07652502 | Physical Exercise During the Cancer Care Pathway(ECOLE) | not yet recruiting | — | 370 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 2 | Jun 26, 2026 | clinicaltrials |
| NCT03088540 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 712 | Regeneron PharmaceuticalsINDUSTRY | 24 | Jun 25, 2026 | clinicaltrials |
| NCT03872401 | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke(VESALIUS-CV) | completed | Phase 3 | 12,301 | AmgenINDUSTRY | 33 | Jun 25, 2026 | clinicaltrials |
| NCT04219254 | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 197 | BioInvent International ABINDUSTRY | 7 | Jun 25, 2026 | clinicaltrials |
| NCT02834884 | SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access(SPECTA) | recruiting | — | 4,975 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 20 | Jun 24, 2026 | clinicaltrials |
| NCT00196742 | Fabry Disease Registry & Pregnancy Sub-registry | recruiting | — | 9,000 | Genzyme, a Sanofi CompanyINDUSTRY | 44 | Jun 23, 2026 | clinicaltrials |
| NCT05555732 | Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | active not recruiting | Phase 3 | 1,170 | Daiichi SankyoINDUSTRY | 29 | Jun 23, 2026 | clinicaltrials |
| NCT07207304 | Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes | completed | N/A | 153 | Iuliu Hatieganu University of Medicine and PharmacyOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05325866 | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-301) | terminated | Phase 1 / Phase 2 | 260 | AmgenINDUSTRY | 26 | Jun 22, 2026 | clinicaltrials |
| NCT05696626 | Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation(ELAINEIII) | recruiting | Phase 3 | 600 | LeonaBioINDUSTRY | 17 | Jun 22, 2026 | clinicaltrials |
| NCT03441113 | Extended Access of Momelotinib in Adults With Myelofibrosis | active not recruiting | Phase 2 | 237 | GlaxoSmithKlineINDUSTRY | 20 | Jun 18, 2026 | clinicaltrials |
| NCT04475939 | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer(ZEAL-1L) | completed | Phase 3 | 666 | GlaxoSmithKlineINDUSTRY | 27 | Jun 18, 2026 | clinicaltrials |
| NCT04623775 | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 468 | Bristol-Myers SquibbINDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | recruiting | Phase 3 | 400 | Ascentage Pharma Group Inc.INDUSTRY | 19 | Jun 18, 2026 | clinicaltrials |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects(CANOPY-1) | terminated | Phase 3 | 673 | Novartis PharmaceuticalsINDUSTRY | 41 | Jun 17, 2026 | clinicaltrials |
| NCT04702880 | A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer | completed | Phase 2 | 135 | Bristol-Myers SquibbINDUSTRY | 11 | Jun 17, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC(KANGUROO) | recruiting | Phase 2 / Phase 3 | 71 | Urovant Sciences GmbHINDUSTRY | 16 | Jun 15, 2026 | clinicaltrials |
| NCT04705389 | SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines(SUMMERTIME) | active not recruiting | N/A | 35 | University Hospital, ToursOTHER | 10 | Jun 12, 2026 | clinicaltrials |
| NCT05430971 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry | recruiting | — | 200 | Immune Oncology Research InstituteOTHER | 15 | Jun 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials